Xalnesiran with or without an Immunomodulator in Chronic Hepatitis BJinlin Hou, Edward Gane, Wenhong Zhang et al.|New England Journal of Medicine|2024Cited by 77
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019Chiara Fanciulli, Juan Berenguer, Carmen Busca et al.|HIV Medicine|2022Cited by 28
Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be SignificantJuan Berenguer, Inmaculada Jarrín, Leire Pérez‐Latorre et al.|Open Forum Infectious Diseases|2018Cited by 28
Clinical experience with integrase inhibitors in HIV-2-infected individuals in SpainSilvia Requena, Carmen Raya, Carmen de Mendoza et al.|Journal of Antimicrobial Chemotherapy|2019Cited by 20
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimensDaniel Podzamczer, Antonio Rivero, Arkaitz Imaz et al.|Journal of Antimicrobial Chemotherapy|2023Cited by 10